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hybridizationanalysisAbstract Chromophobe renal cell carcinoma (ChRCC) with neuroendocrine differentiation/
morphology (NED/NEM) is exceedingly rare. We present three cases of ChRCC with NED/NEM,
two of which showed positivity for neuroendocrine markers on immunohistochemical analysis.
Patients ranged in age from 49 to 79 years (mean: 64.3 years). One of the three patients died of
metastatic disease to multiple organs. Of the remaining two patients, one is currently alive without
disease and the other is alive with disease. Histologically, all three tumors were composed of
conventional ChRCC and NEM showed glandular and rosette formation. Immunohistochemically,
tumor cells were positive for CK7, KAI1, E-cadherin, and c-kit in both ChRCC and
neuroendocrine areas in three cases. CD56 and synaptophysin immunoreactivity were detected
in two cases; in only the neuroendocrine area in one case and in both components in the other.
Neuroendocrine granules were ultrastructurally observed at both neuroendocrine and conventional
areas of ChRCC. Array comparative genomic hybridization (CGH) study indicated losses of
chromosomes 1, 2, 6, 10, 17, 21, and Y in both conventional ChRCC and NED in one case. In
addition, losses of chromosomes 1, 2, 4, 6, 9, 10, 13, 16p, 17, and 21 were observed in both⁎ Corresponding author at: Department of Diagnostic Pathology, Kansai Medical University, Hirakata Hospital, 2-3-1 Shinmachi, Hirakata, Osaka,
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32 C. Ohe et al.components of the remaining one tumor. Furthermore, loss of chromosome 5 was identified only in
the neuroendocrine area in this case. We concluded that the neuroendocrine area may reflect
dedifferentiation within ChRCC. It is possible that losses of chromosomes 4, 5, and 16p may be
involved in the neuroendocrine differentiation or progression of ChRCC.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Chromophobe renal cell carcinoma (ChRCC) accounts
for about 5% of total renal neoplasms. ChRCC is
recognized as a distinct subtype of RCC with a relatively
good prognosis compared to clear cell RCC. In contrast,
tumors with sarcomatoid changes and perinephric invasion
may show an aggressive clinical course [1,2]. Cytogenet-
ically, losses of chromosomes 1, 2, 6, 10, 13, 17, and 21 are
frequently noted in conventional ChRCC [3]. The gains of
several chromosomes have been reported in sarcomatoid
ChRCC [4]. Two cases of ChRCC with neuroendocrine
differentiation (NED) have been reported [5,6]. It was
suggested that the neuroendocrine area may occur as a
result of dedifferentiation within ChRCC [5,6]. However,
to our knowledge, there have been no reports regarding
genetic alterations in ChRCC with NED. Here, we present
two cases of ChRCC with NED and one case of ChRCC
with neuroendocrine morphology (NEM), and discuss the
clinicopathological findings and genetic alterations.2. Materials and methods
Three cases of ChRCC with NEM were extracted for
this study from 105 ChRCCs diagnosed in Kansai Medical
University Hirakata Hospital (case 1) and Kochi Red Cross
Hospital, including consultation files (cases 2 and 3; case 3
originated from Tonami General Hospital) between 2006
and 2013. Among these three cases of ChRCC with NEM,
two showed positivity for neuroendocrine markers on
immunohistochemical analysis. Therefore, a diagnosis of
ChRCC with NED was made in these two cases (cases 1
and 2), while the third was diagnosed as ChRCCwith NEM
(case 3). One case (case 2) was described previously [6].
2.1. Morphology and immunophenotypic studies
For all formalin-fixed and paraffin-embedded (FFPE)
renal tumors from nephrectomy, sections 3 μm thick were
stained with hematoxylin and eosin (H&E). Representa-
tive blocks from each case were selected for immunohis-
tochemical studies using the Ventana Autostainer
Benchmark XT (Ventana Medical Inc., Tucson, AZ).Primary antibodies to the following antigens were
employed: CK7 (OV-TL 12/30, 1:100; DAKO, Glostrup,
Denmark), KAI1 (G2, 1:100; Santa Cruz Biotechnology,
Santa Cruz, CA), CD117 (polyclonal, prediluted; Nichirei,
Tokyo, Japan), E-cadherin (NCH-38, 1:100; DAKO), CD56
(1B6, prediluted; Nichirei), synaptophysin (27G12, prediluted;
Nichirei), and chromogranin A (LK2H10, prediluted; Japan
Tanner, Osaka, Japan). The primary antibodies were
visualized using a Ventana I-VIEW DAB Universal kit
(Roche Diagnostics KK, Tokyo, Japan).2.2. Ultrastructural studies
Materials included in paraffin blocks from two cases
(cases 1 and 2) were processed for transmission electron
microscopy to evaluate the presence of neuroendocrine
granules. Small sectionswere extracted fromboth conventional
ChRCC and neuroendocrine areas. Specimens were depar-
affinized, fixed in 2% osmium tetroxide, and embedded in
epoxy resin. Ultrathin sections were cut with a Reichert
microtome, stained with uranyl acetate and lead citrate, and
examinedwith an electronmicroscope (JEM-1400A; JEOL,
Tokyo, Japan). Micrographs were taken at different
magnifications (×4000–×50000).2.3. Genomic DNA extraction and array compara-
tive genomic hybridization
Written informed consent was obtained from two patients
(cases 1 and 2) for genetic studies. Genomic DNA was
extracted from FFPE tissue samples as described previously
[7]. The use of tissue samples for all experiments was
approved by the Oita University Ethics Committee (approval
no. 700) in accordancewith theEthicalGuidelines forClinical
Research of the Japanese Ministry of Health, Labour and
Welfare, 2008 (http://www.mhlw.go.jp/english/). The Agi-
lent Human Genome Array CGH microarray 44K (Agilent
Technologies, PaloAlto, CA)was used for array-comparative
genomic hybridization (CGH) analysis. Genomic DNA was
extracted from the tumor in both conventional ChRCC and
neuroendocrine areas, and the non-tumor region from the
Table 1 Summary of clinicopathological information of ChRCC with neuroendocrine differentiation (cases 1 and 2)/neuroendocrine
morphology (case 3).
Case Age/sex Clinical presentation Size (cm) TNM classification Clinical outcome Follow-up
(months)
1 49/M Incidental 2.2 × 2.0 pT3aN0M0 No metastasis or recurrence 9
2 79/M Significant
weight loss
22 × 12 pT3bN0M0 Alive with disease (suspected lung and
periaortic lymph node metastases by CT scan)
39
3 65/M Right flank pain 11.5 × 10.5 pT3aNXM0 Died of disease (lung, liver, and bone metastases) 14
M: male, F: female.
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regionwas hybridized (each sample: 2 μg), andwas subjected
to array-CGH in accordance with the manufacturer's
instructions. The arrays were washed, scanned with an
Agilent 2565AA DNA microarray scanner (Agilent Tech-
nologies), and processed with the Agilent Feature Extraction
software (version 9. 5.3.1; Agilent Technologies) with linear
normalization (protocol CGH-v4_95_Feb07) and the result-
ing data were subsequently imported into the DNAAnalytics
v. 4.0.81 software package (Agilent Technologies). Aberrant
regions were determined by the Aberration DetectionMethod
(ADM)-2 algorithm at a threshold of 10.0 in DNAAnalytics.
To detect gains and losses of chromosome regions, we set the
values of parameters for aberration filters as follows:
minimum number of probes in region 2, minimum absolute
average log2 ratio for region 0.15, maximum number of
aberrant regions 10000, and percentage penetrance per
feature 0. The data obtained in array CGH analysis areFig. 1 Representative macroscopic results. A: The tumor was wel
surface, a tumor with cystic change was observed outside the capsuleavailable at the GEO database (http://www.ncbi.nlm.nih.gov/
geo/; accession numbers GSE52641).
3. Results
3.1. Clinical features
The basic clinicopathological data of the patients are
summarized in Table 1. Briefly, the patients ranged in age
from 49 to 79 years with a mean of 64.3 years, and all
patients were men. One (case 3) of three patients died of
metastatic cancer to multiple organs (lung, liver, and bone)
14 months after nephrectomy. Of the remaining two
patients, one (case 1) is currently alive without disease
9 months after partial nephrectomy, and the other (case 2)
is alive with suspected lung and periaortic lymph node
metastasis by computed tomography (CT) scan 39 months
after surgery.l-circumscribed and beige in color (bar = 1 cm). B: On the cut
and in the perinephric fat tissue (arrow) (bar = 1 cm).
Fig. 2 Representative H&E staining of chromophobe RCC (ChRCC) with neuroendocrine differentiation (cases 1 and 2)/neuroendocrine
morphology (case 3). A–C, J–L, case 1; D–F, case 2; G–I, case 3. A, D, and G: Conventional area of ChRCC. B, E, and H: The smaller
neoplastic cells showed glandular and rosette formation. C, F, and I: Neuroendocrine morphology and ChRCC component showed a gradual
transition with an area of smaller cells and nuclear overcrowding. J: A tubular and cystic pattern was also identified. K: The small neoplastic
cells with nuclear overcrowding were observed. L: Mitotic figures were seen. (A–I, L: original magnification ×400, J–K: ×200).
Table 2 Results of immunohistochemistry.
case CK7 KAI1 E. cadherin c-kit CD56 Synaptophysin Chromogranin A
1. ChRCC d+ d+ d+ d+ d+ f+ −
Neu d+ d+ d+ d+ d+ d+ −
2. ChRCC d+ d + d+ d+ −* − −
Neu d+ d+ d+ d+ d+ f+ −
3. ChRCC d+ d+ d+ d+ − − −
Neu d+ f+ d+ d+ −* − −
ChRCC: conventional chromophobe renal cell carcinoma; Neu: neuroendocrine area; +: positive; −: negative, −*: basically negative, but a small
number cells showed expression; d: diffuse; f: focal.
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Fig. 3 Representative results of immunohistochemistry in morphologically transitional area. A–D (case 2): Typical chromophobe
RCC (ChRCC) and neuroendocrine areas are observed at the right and left sides, respectively. A. CK7, B. KAI1, C. E-cadherin, D. c-kit.
E-H (case 1): E and F: CD56 and synaptophysin in the typical ChRCC area. G and H: CD56 and synaptophysin in the neuroendocrine
area. (A–H: original magnification ×400).
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The largest dimensions of the tumors ranged from
2.2 cm to 22 cm (average, 11.9 cm). All of the tumors
were well-circumscribed single masses, brown to beige in
color (Fig. 1A). In two cases (cases 1 and 2), cancer
invasion to perinephric fat tissue was seen. In case 3,
cancer invasion to renal sinus fat was recognized. In case
1, the tumor with cystic change was observed outside the
capsule and in the perinephric fat tissue (Fig. 1B).Representative H&E figures of three cases are shown in
Fig. 2 (A–C, case 1; D–F, case 2; G–I, case 3).
Histologically, all three tumors consisted of large cells with
abundant reticular translucent cytoplasm and smaller cells
with scant eosinophilic cytoplasm. The cell borders were
distinct and perinuclear haloeswere identified in eosinophilic
cells (Fig. 2A, D, and G). The nuclei in both types showed
slight pleomorphism with wrinkling of the nuclear mem-
brane, and binucleated cells were also seen. These
characteristics were consistent with typical and eosinophilic
Fig. 4 Ultrastructural observation of tumor cells (case 1). A: Neuroendocrine area of ChRCC. Neuroendocrine granules were distributed
at the periphery of the tumor cytoplasm (arrows) (×6000, bar = 5 μm). Inset shows neuroendocrine granules (×50000, bar = 0.5 μm).
B: Typical area of ChRCC. Neuroendocrine granules were present at the peripheral of the tumor cytoplasm (arrows) (×4000, bar = 5 μm).
The inset shows neuroendocrine granules (×30000, bar = 0.5 μm).
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inant, but tubular and cystic patterns were also seen in case 1
(Fig. 2J). In two of three cases (cases 1 and 3), the
eosinophilic cell component was predominant. In the
eosinophilic cell proliferation area, smaller neoplastic cells
were observed with nuclear overcrowding (Fig. 2K). In
addition, glandular and rosette formations of small neoplastic
cells were also seen (Fig. 2B, E, andH). This neuroendocrine
morphology (NEM) and ChRCC component showed a
gradual transition with the area of smaller neoplastic cells
and nuclear overcrowding (Fig. 2C, F, and I). Sarcomatoid
changes were seen in two cases, one (case 2) accounted for
approximately 1% of the neoplasm, and another accounted
about 15% (case 3). Calcification was also observed in all
cases. In one case (case 1), mitotic figures were recognized
up to 5 mitoses per 10 high power fields (HPF) (Fig. 2L),
although mitosis was hardly seen in the other two cases.
3.3. Immunohistochemical findings
Immunohistochemical results are summarized in
Table 2. Both conventional ChRCC area and neuroendo-
crine area of all three tumors showed diffuse reactivity for
CK7, KAI1, E-cadherin, and c-kit (Fig. 3A–D). In the
conventional ChRCC areas, one case (case 1) showed
positivity for CD56 and synaptophysin (Fig. 3E–F). In
neuroendocrine areas of two cases (cases 1 and 2), CD56 and
synaptophysin showed reactivity (Fig. 3G–H), but one case(case 3) was negative for neuroendocrine markers. All cases
were negative for chromogranin A.3.4. Ultrastructural findings
The ultrastructure of the tumor cells in two cases
showed marked formalin fixation artifacts. In both of these
cases, the cytoplasm of the tumor cells contained dense-
cored neuroendocrine granules measuring about 150–
350 nm. These granules were observed in the cytoplasm of
both the neuroendocrine area (Fig. 4A) and the conven-
tional area of ChRCC (Fig. 4B).3.5. Genetic findings
In case 2, chromosomes 1, 2, 6, 10, 17, 21, and Y were
lost in both the conventional ChRCC area and neuroen-
docrine area (Fig. 5A:a–b). In case 1, losses of
chromosomes 1, 2, 4, 6, 9, 10, 13, 16p, 17, and 21 were
observed in both components of the tumor (Fig. 5A:c–d),
whereas loss of chromosome 5 was identified only in the
neuroendocrine area (Fig. 5A:d). As shown in Fig. 5A-c, A-
d, and B, deletion at 16p including 16p13 contained a small
area of copy number loss. No chromosomal gains were
observed in the two tumors examined.
Fig. 5 A: Array CGH profiles of chromophobe RCC (ChRCC) with neuroendocrine differentiation (NED) cases. Whole genomic profiles of case 1 (a, b) and case 2 (c, d) are shown.
Horizontal lines: oligonucleotide probes are shown in order from chromosomes 1–22. Vertical lines above the center represent regions of gain, and those below the center represent
regions of loss. The shaded areas indicate regions of copy number aberrations according to the ADM-2 algorithm. a: Typical ChRCC area of case 1. b: ChRCC with NED area of case 1.
In both areas, losses of chromosomes 1, 2, 6, 10, 17, 21, and Y were seen. c: Typical ChRCC area of case 2. d: ChRCC with NED area of case 2. In both components, losses of
chromosomes 1, 2, 4, 6, 9, 10, 13, 16p, 17, and 21 were observed (the red arrow indicates loss of chromosome 16p). Loss of chromosome 5 was also noted only in the neuroendocrine area
(blue arrow). B: Detailed genomic profiles of chromosome 16 indicated by a red arrow in A-c and d are shown. Horizontal lines above the center represent regions of gain, and those
below the center represent regions of loss. The deletion at 16p including 16p13 contained a small area of copy number loss.
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Some primary renal tumors showing NED, including
carcinoid tumor, small cell carcinoma, and large cell
neuroendocrine carcinoma, have been reported [8–12]. In
the kidney, it is rare that neuroendocrine components are
admixed with RCC components. There have been only a few
reports of mucinous tubular spindle cell carcinoma of the
kidney with NED [13,14], and ChRCCwith NED [5,6]. This
phenomenon should be strictly distinguished from primary
neuroendocrine tumors of the kidney [8–12]. A case of
combined ChRCC and carcinoid tumor without overlap of
these components has been described [15]. On the other hand,
a case of tubular ChRCC resembling neuroendocrine tumor
has also been noted [16]. These cases were also different from
ChRCC with NED. All three cases had no past history of
neuroendocrine tumor, therefore a renal metastasis from
another site would be excluded.
Parada and Pena described the first case of ChRCC with
NED in a 56-year-old man [5]. The authors reported that the
tumor showed a mixture of typical and eosinophilic patterns of
ChRCC with neuroendocrine areas. Immunohistochemically,
both ChRCC and neuroendocrine areas showed positivity
for CK7 and c-kit. The neuroendocrine areas were positive for
chromogranin A and CD56, while there was no evidence of
neuroendocrine expression in the conventional ChRCC areas.
In this study, histological and immunohistochemical
features were consistent with the diagnosis of ChRCC. In
addition, NEM including glandular and rosette formations
was recognized on light microscopy. In two of three cases, we
diagnosed ChRCC with NED because the area of NEM was
immunohistochemically positive for neuroendocrinemarkers.
Notwithstanding, one case was diagnosed as ChRCC with
NEM, as NEM showed no reaction for neuroendocrine
markers. Both ChRCC and NEM areas showed the same
immunohistochemical pattern of CK7,KAI1, E-cadherin, and
c-kit, known to as ChRCCmarkers [1,2]. Interestingly, in this
study, neuroendocrine areas as well as conventional ChRCC
areas in one case were immunohistochemically positive for
neuroendocrine markers and neuroendocrine granules were
also observed on ultrastructural examination. These immu-
nohistochemical and ultrastructural results suggested that
ChRCC and NED area may share the same origin.
With regard to the pathogenesis of primary neuroendo-
crine tumor, it has been suggested that neuroendocrine
tumors may originate from i) misplaced or entrapped neural
crest, ii) neuroendocrine differentiation of primitive totipo-
tent stem cells, or iii) preexisting neuroendocrine cell
hyperplasia from metaplastic/teratomatous epithelium, be-
cause neuroendocrine cells are basically absent from the
normal kidney [11]. In the case of ChRCC with NED/NEM,
we suggest that differentiation toward neuroendocrine cells
may show dedifferentiation similar to the sarcomatoid
change or rhabdoid differentiation.In this study, one patient died of the tumor 14 months after
the pathological diagnosis, and lung and lymph node
metastases were suspected by CT scan in one patient. With
regard to the prognostic parameters for ChRCC, sarcomatoid
change and higher pT stage (pT3/4) were reported to be
correlated with aggressive behavior [2,17]. In the present
study, two of three cases had a huge mass with focal
sarcomatoid growth. ChRCCwith sarcomatoid differentiation
is known to its aggressive clinical behavior. In one of the
largest series to date, the mean percentage of sarcomatoid
differentiationwas 67% [18]. However, in our cases, the areas
showing sarcomatoid change represented a low proportion
of each tumor. Therefore, we estimated that the sarcomatoid
change in our case had a relatively low impact on patient's
prognosis. On the other hand, one case was at high pT stage
(pT3a) regardless of the small renal mass without
sarcomatoid lesions. Accordingly, pathologists should be
aware that NED/NEM in ChRCC may also reflect a poor
prognosis. Recently, Paner et al. proposed chromophobe
tumor grading based on the assessment of geographic
nuclear crowding and anaplasia, because it is controversial
whether the Fuhrman nuclear grade of ChRCC has
prognostic utility or not [19]. In the present study, the
ChRCC showed a gradual transition to NEMwith an area of
smaller neoplastic cells and nuclear overcrowding. Conse-
quently, the geographic nuclear crowding proposed by
Paner et al. may be the essential first step for ChRCC with
NEM. In terms of prognosis, it is important to distinguish
ChRCC with NEM from renal small cell onococytoma with
pseudorosettes [20]. Pathologists should recognize this
tumor entity, because these two tumors were different
from benign or malignant.
Here, we presented the first report of NED in ChRCCwith
genetic abnormalities. Losses of chromosomes 1, 2, 6, 10, 13,
17, and 21 are frequently observed in ChRCC [3]. In addition,
gains of chromosomes 4, 7, 15, 19, and 20 are often identified
irrespective of Paner grade [21]. In the present study,
however, no chromosomal gain was observed in two cases
of ChRCC examined. Chromosomal aberrations of one case
were almost the same as the results reported previously in
ChRCC, but the other case showed additional copy number
aberrations, such as losses of chromosomes 4, 6, and 16p.
Furthermore, loss of chromosome 5 was selectively identified
in the neuroendocrine area. To our knowledge, loss of
chromosome 16p in ChRCC has not been reported previously
[22]. In addition, loss of chromosome 4 seems to be less
frequent in ChRCC and losses of chromosomes 3, 5, and 9
were observed in 23%–40% of ChRCC cases [22]. Losses of
chromosome 4, 4p, or 4q have been noted in some
neuroendocrine tumors at other anatomical sites, including
the thyroid gland, digestive tract, thymus, and skin [23–26].
Loss of chromosome 5q was detected in 10% of thymus
neuroendocrine tumors, and loss of heterozygosity (LOH) in
chromosome 5q occurred in all tumors of pulmonary large cell
39Chromophobe RCC with NED/NEMneuroendocrine carcinoma [25,27]. LOH of chromosome
16p13 was identified in a case of malignant islet cell tumor
associated with tuberous sclerosis, consisted with the present
findings [28]. Similar to clear cell RCC, losses of
chromosomes 4p and 9p may be associated with poor
prognosis [29]. Taking all of these results into consideration,
it is possible that losses of chromosomes 4, 5, and 16p may
be involved in the neuroendocrine differentiation or
progression of ChRCC. Further large-scale studies are
needed to identify the genes responsible for neuroendocrine
differentiation in ChRCC.5. Conclusions
Wereported twocases ofChRCCwithNEDandone case of
ChRCC with NEM. The NED/NEM may reflect dedifferenti-
ation within ChRCC. It is possible that losses of chromosomes
4, 5, and 16p are involved in the neuroendocrine differentiation
or progression of ChRCC. We suggest that ChRCC with
NED/NEM may show an aggressive clinical course.
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